Amy Kirkwood, MSc, of the Cancer Research UK & UCL Cancer Trials Centre, at the University College London, discusses results from the randomized phase III UKALL trial, which evaluated the impact of high-dose methotrexate on central nervous system relapse in children and young adults with acute lymphoblastic leukemia or lymphoblastic lymphoma. Ms. Kirkwood and colleagues presented the study’s results at the 2022 American Society of Hematology Annual Meeting.